目次

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 40)
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 STUDY SCOPE
1.4 YEARS CONSIDERED
1.5 CURRENCY CONSIDERED
1.6 RESEARCH LIMITATIONS
1.7 STAKEHOLDERS

2 RESEARCH METHODOLOGY (Page No. - 44)
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
FIGURE 2 BREAKDOWN OF PRIMARIES
2.2 MARKET ESTIMATION METHODOLOGY
FIGURE 3 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS), 2021
FIGURE 4 MARKET SIZE (USD MILLION)
FIGURE 5 MARKET: FINAL CAGR PROJECTIONS (2023−2028)
FIGURE 6 MARKET: CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
2.3 MARKET DATA ESTIMATION AND TRIANGULATION
FIGURE 7 DATA TRIANGULATION METHODOLOGY
2.4 INDUSTRY INSIGHTS
2.5 STUDY ASSUMPTIONS
2.6 GLOBAL RECESSION IMPACT: MARKET
TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021-2027 (% GROWTH)
TABLE 2 US HEALTH EXPENDITURE, 2019-2022 (USD MILLION)
TABLE 3 US HEALTH EXPENDITURE, 2023-2027 (USD MILLION)

3 EXECUTIVE SUMMARY (Page No. - 54)
FIGURE 8 NGS SAMPLE PREPARATION MARKET, BY PRODUCT & SERVICE, 2022 VS. 2028 (USD MILLION)
FIGURE 9 MARKET, BY WORKFLOW, 2022 VS. 2028 (USD MILLION)
FIGURE 10 MARKET, BY SAMPLE TYPE, 2022 VS. 2028 (USD MILLION)
FIGURE 11 MARKET, BY METHOD, 2022 VS. 2028 (USD MILLION)
FIGURE 12 MARKET, BY APPLICATION, 2022 VS. 2028 (USD MILLION)
FIGURE 13 MARKET, BY END USER, 2022 VS. 2028 (USD MILLION)
FIGURE 14 GEOGRAPHICAL SNAPSHOT OF MARKET

4 PREMIUM INSIGHTS (Page No. - 59)
4.1 MARKET OVERVIEW
FIGURE 15 ADVANCEMENTS IN NGS PLATFORMS TO DRIVE GROWTH
4.2 NORTH AMERICA: MARKET, BY PRODUCT & SERVICE AND COUNTRY (2022)
FIGURE 16 REAGENTS & CONSUMABLES ACCOUNTED FOR LARGEST MARKET SHARE IN 2022
4.3 MARKET, BY APPLICATION, 2022 VS. 2028
FIGURE 17 DISEASE DIAGNOSTICS SEGMENT TO DOMINATE MARKET IN 2028
4.4 MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 18 CHINA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD

5 MARKET OVERVIEW (Page No. - 62)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 19 NGS SAMPLE PREPARATION MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
TABLE 4 MARKET: IMPACT ANALYSIS
5.2.1 DRIVERS
5.2.1.1 Constant innovations in NGS platforms
5.2.1.2 Increased availability of advanced NGS systems at low costs
FIGURE 20 COST PER HUMAN GENOME, 2001-2021
5.2.1.3 Use of NGS as substitute for PCR
5.2.1.4 Greater efficiency of genotyping and preparation protocols
5.2.2 RESTRAINTS
5.2.2.1 Presence of alternative technologies
5.2.2.2 Limited expertise and sequencing capabilities of individual laboratories
5.2.3 OPPORTUNITIES
5.2.3.1 Increasing collaborations and partnerships among key players
5.2.4 CHALLENGES
5.2.4.1 Ethical and privacy issues in health data
5.3 TECHNOLOGY ANALYSIS
5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 21 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.5 SUPPLY AND VALUE CHAIN ANALYSIS
5.5.1 SUPPLY CHAIN ANALYSIS OF MARKET
FIGURE 22 MARKET: SUPPLY CHAIN ANALYSIS
5.5.2 VALUE CHAIN ANALYSIS OF MARKET
FIGURE 23 MARKET: VALUE CHAIN ANALYSIS
5.6 ECOSYSTEM ANALYSIS
FIGURE 24 MARKET: ECOSYSTEM ANALYSIS
5.7 PORTER’S FIVE FORCES ANALYSIS
TABLE 5 MARKET: PORTER’S FIVE FORCES ANALYSIS
5.7.1 THREAT OF NEW ENTRANTS
5.7.2 THREAT OF SUBSTITUTES
5.7.3 BARGAINING POWER OF BUYERS
5.7.4 BARGAINING POWER OF SUPPLIERS
5.7.5 INTENSITY OF COMPETITIVE RIVALRY
5.8 REGULATORY ANALYSIS
5.8.1 FDA APPROVALS
5.8.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 6 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 7 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 8 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 9 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.9 PRICING ANALYSIS
TABLE 10 AVERAGE SELLING PRICE OF KEY PLAYERS, BY PRODUCT
5.9.1 AVERAGE SELLING PRICE TREND ANALYSIS
5.10 PATENT ANALYSIS
FIGURE 25 PATENT FILING TRENDS FOR TOP 5 IPC MAIN CLASSES, 2018−2020
5.11 KEY CONFERENCES AND EVENTS IN 2023
5.11.1 CONFERENCES ON NGS SAMPLE PREPARATION IN 2023
TABLE 11 CONFERENCES ON NGS SAMPLE PREPARATION (2023)
5.12 KEY STAKEHOLDERS AND BUYING CRITERIA
5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 26 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS IN MARKET
5.12.2 BUYING CRITERIA FOR MARKET
FIGURE 27 KEY BUYING CRITERIA FOR END USERS

6 NGS SAMPLE PREPARATION MARKET, BY PRODUCT & SERVICE (Page No. - 79)
6.1 INTRODUCTION
TABLE 12 MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
6.2 WORKSTATIONS/INSTRUMENTS
6.2.1 INCREASING DEMAND FOR AUTOMATION OF NGS TO PROPEL MARKET
TABLE 13 MARKET FOR WORKSTATIONS/INSTRUMENTS, BY REGION, 2021-2028 (USD MILLION)
TABLE 14 NORTH AMERICA: MARKET FOR WORKSTATIONS/INSTRUMENTS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 15 EUROPE: MARKET FOR WORKSTATIONS/INSTRUMENTS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 16 ASIA PACIFIC: MARKET FOR WORKSTATIONS/INSTRUMENTS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 17 LATIN AMERICA: MARKET FOR WORKSTATIONS/INSTRUMENTS, BY COUNTRY, 2021-2028 (USD MILLION)
6.3 REAGENTS & CONSUMABLES
6.3.1 GROWING USE OF CONSUMABLES FOR NGS SAMPLE PREPARATION TO DRIVE MARKET
TABLE 18 MARKET FOR REAGENTS & CONSUMABLES, BY REGION, 2021-2028 (USD MILLION)
TABLE 19 NORTH AMERICA: MARKET FOR REAGENTS & CONSUMABLES, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 20 EUROPE: MARKET FOR REAGENTS & CONSUMABLES, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 21 ASIA PACIFIC: MARKET FOR REAGENTS & CONSUMABLES, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 22 LATIN AMERICA: MARKET FOR REAGENTS & CONSUMABLES, BY COUNTRY, 2021-2028 (USD MILLION)
6.4 SERVICES
6.4.1 INCREASING INSTALLATION OF NGS PLATFORMS TO SUPPORT MARKET
TABLE 23 MARKET FOR SERVICES, BY REGION, 2021-2028 (USD MILLION)
TABLE 24 NORTH AMERICA: MARKET FOR SERVICES, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 25 EUROPE: MARKET FOR SERVICES, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 26 ASIA PACIFIC: MARKET FOR SERVICES, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 27 LATIN AMERICA: MARKET FOR SERVICES, BY COUNTRY, 2021-2028 (USD MILLION)

7 NGS SAMPLE PREPARATION MARKET, BY WORKFLOW (Page No. - 89)
7.1 INTRODUCTION
TABLE 28 MARKET, BY WORKFLOW, 2021-2028 (USD MILLION)
7.2 DNA FRAGMENTATION & LIBRARY PREPARATION
7.2.1 AVAILABILITY OF PRODUCTS FROM VARIOUS PLAYERS TO DRIVE MARKET
TABLE 29 MARKET FOR DNA FRAGMENTATION & LIBRARY PREPARATION, BY REGION, 2021-2028 (USD MILLION)
TABLE 30 NORTH AMERICA: MARKET FOR DNA FRAGMENTATION & LIBRARY PREPARATION, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 31 EUROPE: MARKET FOR DNA FRAGMENTATION & LIBRARY PREPARATION, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 32 ASIA PACIFIC: MARKET FOR DNA FRAGMENTATION & LIBRARY PREPARATION, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 33 LATIN AMERICA: MARKET FOR DNA FRAGMENTATION & LIBRARY PREPARATION, BY COUNTRY, 2021-2028 (USD MILLION)
7.3 TARGET ENRICHMENT
7.3.1 LAUNCH OF ADVANCED TARGET ENRICHMENT SOLUTIONS AND TECHNOLOGIES TO DRIVE MARKET
TABLE 34 MARKET FOR TARGET ENRICHMENT, BY REGION, 2021-2028 (USD MILLION)
TABLE 35 NORTH AMERICA: MARKET FOR TARGET ENRICHMENT, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 36 EUROPE: MARKET FOR TARGET ENRICHMENT, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 37 ASIA PACIFIC: MARKET FOR TARGET ENRICHMENT, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 38 LATIN AMERICA: MARKET FOR TARGET ENRICHMENT, BY COUNTRY, 2021-2028 (USD MILLION)
7.4 QUALITY CONTROL
7.4.1 RISING NUMBER OF RESEARCH ACTIVITIES REQUIRING QUALITY-ASSURED SAMPLES TO PROPEL MARKET
TABLE 39 MARKET FOR QUALITY CONTROL, BY REGION, 2021-2028 (USD MILLION)
TABLE 40 NORTH AMERICA: MARKET FOR QUALITY CONTROL, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 41 EUROPE: MARKET FOR QUALITY CONTROL, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 42 ASIA PACIFIC: MARKET FOR QUALITY CONTROL, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 43 LATIN AMERICA: MARKET FOR QUALITY CONTROL, BY COUNTRY, 2021-2028 (USD MILLION)

8 NGS SAMPLE PREPARATION MARKET, BY SAMPLE TYPE (Page No. - 98)
8.1 INTRODUCTION
TABLE 44 MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
8.2 DNA
8.2.1 RISING NUMBER OF CANCER CASES AND GROWING R&D INVESTMENTS FOR STUDYING DNA SAMPLES TO DRIVE MARKET
TABLE 45 MARKET FOR DNA, BY REGION, 2021-2028 (USD MILLION)
TABLE 46 NORTH AMERICA: MARKET FOR DNA, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 47 EUROPE: MARKET FOR DNA, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 48 ASIA PACIFIC: MARKET FOR DNA, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 49 LATIN AMERICA: MARKET FOR DNA, BY COUNTRY, 2021-2028 (USD MILLION)
8.3 RNA
8.3.1 DECREASED COSTS OF GENOME SEQUENCING TO AUGMENT MARKET
TABLE 50 MARKET FOR RNA, BY REGION, 2021-2028 (USD MILLION)
TABLE 51 NORTH AMERICA: MARKET FOR RNA, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 52 EUROPE: MARKET FOR RNA, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 53 ASIA PACIFIC: MARKET FOR RNA, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 54 LATIN AMERICA: MARKET FOR RNA, BY COUNTRY, 2021-2028 (USD MILLION)

9 NGS SAMPLE PREPARATION MARKET, BY APPLICATION (Page No. - 104)
9.1 INTRODUCTION
TABLE 55 MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
9.2 DISEASE DIAGNOSTICS
TABLE 56 MARKET FOR DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 57 MARKET FOR DISEASE DIAGNOSTICS, BY REGION, 2021-2028 (USD MILLION)
TABLE 58 NORTH AMERICA: MARKET FOR DISEASE DIAGNOSTICS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 59 EUROPE: MARKET FOR DISEASE DIAGNOSTICS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 60 ASIA PACIFIC: MARKET FOR DISEASE DIAGNOSTICS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 61 LATIN AMERICA: MARKET FOR DISEASE DIAGNOSTICS, BY COUNTRY, 2021-2028 (USD MILLION)
9.2.1 CANCER DIAGNOSTICS
9.2.1.1 Increase in cancer patients globally and launch of NGS-based cancer panels to drive market
TABLE 62 CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2028 (USD MILLION)
TABLE 63 NORTH AMERICA: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 64 EUROPE: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 65 ASIA PACIFIC: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 66 LATIN AMERICA: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
9.2.2 REPRODUCTIVE HEALTH DIAGNOSTICS
9.2.2.1 Increasing awareness about benefits of NIPT and decreasing costs of sequencing to propel market
TABLE 67 REPRODUCTIVE HEALTH DIAGNOSTICS MARKET, BY REGION, 2021-2028 (USD MILLION)
TABLE 68 NORTH AMERICA: REPRODUCTIVE HEALTH DIAGNOSTICS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 69 EUROPE: REPRODUCTIVE HEALTH DIAGNOSTICS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 70 ASIA PACIFIC: REPRODUCTIVE HEALTH DIAGNOSTICS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 71 LATIN AMERICA: REPRODUCTIVE HEALTH DIAGNOSTICS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
9.2.3 INFECTIOUS DISEASE DIAGNOSTICS
9.2.3.1 Growing burden of healthcare-associated infections to aid market
TABLE 72 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION, 2021-2028 (USD MILLION)
TABLE 73 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 74 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 75 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 76 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
9.2.4 OTHER DISEASE DIAGNOSTIC APPLICATIONS
TABLE 77 OTHER DISEASE DIAGNOSTIC APPLICATIONS MARKET, BY REGION, 2021-2028 (USD MILLION)
TABLE 78 NORTH AMERICA: OTHER DISEASE DIAGNOSTIC APPLICATIONS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 79 EUROPE: OTHER DISEASE DIAGNOSTIC APPLICATIONS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 80 ASIA PACIFIC: OTHER DISEASE DIAGNOSTIC APPLICATIONS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 81 LATIN AMERICA: OTHER DISEASE DIAGNOSTIC APPLICATIONS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
9.3 DRUG DISCOVERY
9.3.1 INCREASING USE OF NGS DURING CLINICAL TRIALS TO AUGMENT MARKET
TABLE 82 MARKET FOR DRUG DISCOVERY, BY REGION, 2021-2028 (USD MILLION)
TABLE 83 NORTH AMERICA: MARKET FOR DRUG DISCOVERY, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 84 EUROPE: MARKET FOR DRUG DISCOVERY, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 85 ASIA PACIFIC: MARKET FOR DRUG DISCOVERY, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 86 LATIN AMERICA: MARKET FOR DRUG DISCOVERY, BY COUNTRY, 2021-2028 (USD MILLION)
9.4 AGRICULTURAL & ANIMAL RESEARCH
9.4.1 INCREASED FUNDING AND SUPPORT FOR ANIMAL AND PLANT GENOMICS RESEARCH TO FUEL ADOPTION
TABLE 87 MARKET FOR AGRICULTURAL & ANIMAL RESEARCH, BY REGION, 2021-2028 (USD MILLION)
TABLE 88 NORTH AMERICA: MARKET FOR AGRICULTURAL & ANIMAL RESEARCH, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 89 EUROPE: MARKET FOR AGRICULTURAL & ANIMAL RESEARCH, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 90 ASIA PACIFIC: MARKET FOR AGRICULTURAL & ANIMAL RESEARCH, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 91 LATIN AMERICA: MARKET FOR AGRICULTURAL & ANIMAL RESEARCH, BY COUNTRY, 2021-2028 (USD MILLION)
9.5 OTHER APPLICATIONS
TABLE 92 MARKET FOR OTHER APPLICATIONS, BY REGION, 2021-2028 (USD MILLION)
TABLE 93 NORTH AMERICA: MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 94 EUROPE: MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 95 ASIA PACIFIC: MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 96 LATIN AMERICA: MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)

10 NGS SAMPLE PREPARATION MARKET, BY METHOD (Page No. - 125)
10.1 INTRODUCTION
TABLE 97 MARKET, BY METHOD, 2021-2028 (USD MILLION)
10.2 MANUAL SAMPLE PREPARATION
10.2.1 ERRORS ASSOCIATED WITH NGS MANUAL SAMPLE PREPARATION TO HINDER MARKET
TABLE 98 MARKET FOR MANUAL SAMPLE PREPARATION, BY REGION, 2021-2028 (USD MILLION)
TABLE 99 NORTH AMERICA: MARKET FOR MANUAL SAMPLE PREPARATION, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 100 EUROPE: MARKET FOR MANUAL SAMPLE PREPARATION, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 101 ASIA PACIFIC: MARKET FOR MANUAL SAMPLE PREPARATION, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 102 LATIN AMERICA: MARKET FOR MANUAL SAMPLE PREPARATION, BY COUNTRY, 2021-2028 (USD MILLION)
10.3 MICROFLUIDIC SAMPLE PREPARATION
10.3.1 GROWING APPLICATIONS OF MICROFLUIDIC SAMPLE PREPARATION TO CREATE OPPORTUNITIES
TABLE 103 MARKET FOR MICROFLUIDIC SAMPLE PREPARATION, BY REGION, 2021-2028 (USD MILLION)
TABLE 104 NORTH AMERICA: MARKET FOR MICROFLUIDIC SAMPLE PREPARATION, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 105 EUROPE: MARKET FOR MICROFLUIDIC SAMPLE PREPARATION, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 106 ASIA PACIFIC: MARKET FOR MICROFLUIDIC SAMPLE PREPARATION, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 107 LATIN AMERICA: MARKET FOR MICROFLUIDIC SAMPLE PREPARATION, BY COUNTRY, 2021-2028 (USD MILLION)
10.4 AUTOMATED LIQUID HANDLING-BASED SAMPLE PREPARATION
10.4.1 HIGH PERFORMANCE AND ACCURACY OF AUTOMATED LIQUID HANDLING-BASED SAMPLE PREPARATION TO BOOST GROWTH
TABLE 108 MARKET FOR AUTOMATED LIQUID HANDLING-BASED SAMPLE PREPARATION, BY REGION, 2021-2028 (USD MILLION)
TABLE 109 NORTH AMERICA: MARKET FOR AUTOMATED LIQUID HANDLING-BASED SAMPLE PREPARATION, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 110 EUROPE: MARKET FOR AUTOMATED LIQUID HANDLING-BASED SAMPLE PREPARATION, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 111 ASIA PACIFIC: MARKET FOR AUTOMATED LIQUID HANDLING-BASED SAMPLE PREPARATION, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 112 LATIN AMERICA: MARKET FOR AUTOMATED LIQUID HANDLING-BASED SAMPLE PREPARATION, BY COUNTRY, 2021-2028 (USD MILLION)

11 NGS SAMPLE PREPARATION MARKET, BY END USER (Page No. - 134)
11.1 INTRODUCTION
TABLE 113 MARKET, BY END USER, 2021-2028 (USD MILLION)
11.2 HOSPITALS & CLINICS
11.2.1 ADVANTAGES OF NGS TECHNOLOGY FOR DISEASE DIAGNOSIS OVER CONVENTIONAL METHOD TO FUEL ADOPTION
TABLE 114 MARKET FOR HOSPITALS & CLINICS, BY REGION, 2021-2028 (USD MILLION)
TABLE 115 NORTH AMERICA: MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 116 EUROPE: MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 117 ASIA PACIFIC: MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 118 LATIN AMERICA: MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2021-2028 (USD MILLION)
11.3 ACADEMIC INSTITUTES & RESEARCH CENTERS
11.3.1 AVAILABILITY OF FINANCIAL SUPPORT FOR GENOMICS RESEARCH TO SUPPORT SEGMENT
TABLE 119 MARKET FOR ACADEMIC INSTITUTES & RESEARCH CENTERS, BY REGION, 2021-2028 (USD MILLION)
TABLE 120 NORTH AMERICA: MARKET FOR ACADEMIC INSTITUTES & RESEARCH CENTERS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 121 EUROPE: MARKET FOR ACADEMIC INSTITUTES & RESEARCH CENTERS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 122 ASIA PACIFIC: MARKET FOR ACADEMIC INSTITUTES & RESEARCH CENTERS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 123 LATIN AMERICA: MARKET FOR ACADEMIC INSTITUTES & RESEARCH CENTERS, BY COUNTRY, 2021-2028 (USD MILLION)
11.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
11.4.1 GROWING COLLABORATIONS BETWEEN NGS MARKET PLAYERS AND PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO DRIVE GROWTH
TABLE 124 MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2021-2028 (USD MILLION)
TABLE 125 NORTH AMERICA: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 126 EUROPE: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 127 ASIA PACIFIC: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 128 LATIN AMERICA: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION)
11.5 OTHER END USERS
TABLE 129 MARKET FOR OTHER END USERS, BY REGION, 2021-2028 (USD MILLION)
TABLE 130 NORTH AMERICA: MARKET FOR OTHER END USERS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 131 EUROPE: MARKET FOR OTHER END USERS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 132 ASIA PACIFIC: MARKET FOR OTHER END USERS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 133 LATIN AMERICA: MARKET FOR OTHER END USERS, BY COUNTRY, 2021-2028 (USD MILLION)

12 NGS SAMPLE PREPARATION MARKET, BY REGION (Page No. - 147)
12.1 INTRODUCTION
FIGURE 28 MARKET, BY REGION, 2021 VS. 2028 (USD MILLION)
TABLE 134 MARKET, BY REGION, 2021-2028 (USD MILLION)
12.2 NORTH AMERICA
FIGURE 29 NORTH AMERICA: NGS SAMPLE PREPARATION MARKET SNAPSHOT
TABLE 135 NORTH AMERICA: MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 136 NORTH AMERICA: MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 137 NORTH AMERICA: MARKET, BY WORKFLOW, 2021-2028 (USD MILLION)
TABLE 138 NORTH AMERICA: MARKET, BY SAMPLE TYPE, 2021-2028
TABLE 139 NORTH AMERICA: MARKET, BY METHOD, 2021-2028
TABLE 140 NORTH AMERICA: MARKET, BY APPLICATION, 2021-2028
TABLE 141 NORTH AMERICA: MARKET FOR DISEASE DIAGNOSTICS, BY TYPE, 2021-2028
TABLE 142 NORTH AMERICA: MARKET, BY END USER, 2021-2028
12.2.1 US
12.2.1.1 Favorable regulatory and reimbursement scenarios to drive market
TABLE 143 US: NGS SAMPLE PREPARATION MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 144 US: MARKET, BY WORKFLOW, 2021-2028 (USD MILLION)
TABLE 145 US: MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
TABLE 146 US: MARKET, BY METHOD, 2021-2028 (USD MILLION)
TABLE 147 US: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 148 US: MARKET FOR DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 149 US: MARKET BY END USER, 2021-2028 (USD MILLION)
12.2.2 CANADA
12.2.2.1 Favorable government funding to boost genomics research
TABLE 150 CANADA: NGS SAMPLE PREPARATION MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 151 CANADA: MARKET, BY WORKFLOW, 2021-2028 (USD MILLION)
TABLE 152 CANADA: MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
TABLE 153 CANADA: MARKET, BY METHOD, 2021-2028 (USD MILLION)
TABLE 154 CANADA: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 155 CANADA: MARKET FOR DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 156 CANADA: MARKET, FOR END USER, 2021-2028 (USD MILLION)
12.2.3 NORTH AMERICA: IMPACT OF RECESSION
12.3 EUROPE
TABLE 157 EUROPE: NGS SAMPLE PREPARATION MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 158 EUROPE: MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 159 EUROPE: MARKET, BY WORKFLOW, 2021-2028 (USD MILLION)
TABLE 160 EUROPE: MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
TABLE 161 EUROPE: MARKET, BY METHOD, 2021-2028 (USD MILLION)
TABLE 162 EUROPE: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 163 EUROPE: MARKET FOR DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 164 EUROPE: MARKET, BY END USER, 2021-2028 (USD MILLION)
12.3.1 GERMANY
12.3.1.1 Strong R&D base and presence of several NGS players to support market
TABLE 165 GERMANY: NGS SAMPLE PREPARATION MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 166 GERMANY: MARKET, BY WORKFLOW, 2021-2028 (USD MILLION)
TABLE 167 GERMANY: MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
TABLE 168 GERMANY: MARKET, BY METHOD, 2021-2028 (USD MILLION)
TABLE 169 GERMANY: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 170 GERMANY: MARKET FOR DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 171 GERMANY: MARKET, BY END USER, 2021-2028 (USD MILLION)
12.3.2 UK
12.3.2.1 Use of NGS-based tests for disease diagnosis to augment market
TABLE 172 UK: NGS SAMPLE PREPARATION MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 173 UK: MARKET, BY WORKFLOW, 2021-2028 (USD MILLION)
TABLE 174 UK MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
TABLE 175 UK MARKET, BY METHOD, 2021-2028 (USD MILLION)
TABLE 176 UK: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 177 UK: MARKET FOR DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 178 UK: MARKET, BY END USER, 2021-2028 (USD MILLION)
12.3.3 FRANCE
12.3.3.1 Growing government support for genomics research to propel market
TABLE 179 FRANCE: NGS SAMPLE PREPARATION MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 180 FRANCE: MARKET, BY WORKFLOW, 2021-2028 (USD MILLION)
TABLE 181 FRANCE: MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
TABLE 182 FRANCE: MARKET, BY METHOD, 2021-2028 (USD MILLION)
TABLE 183 FRANCE: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 184 FRANCE: MARKET BY DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 185 FRANCE: MARKET, BY END USER, 2021-2028 (USD MILLION)
12.3.4 REST OF EUROPE
TABLE 186 REST OF EUROPE NGS SAMPLE PREPARATION MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 187 REST OF EUROPE: MARKET, BY WORKFLOW, 2021-2028 (USD MILLION)
TABLE 188 REST OF EUROPE: MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
TABLE 189 REST OF EUROPE: MARKET, BY METHOD, 2021-2028 (USD MILLION)
TABLE 190 REST OF EUROPE: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 191 REST OF EUROPE: MARKET FOR DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 192 REST OF EUROPE: MARKET, BY END USER, 2021-2028 (USD MILLION)
12.3.5 EUROPE: IMPACT OF RECESSION
12.4 ASIA PACIFIC
FIGURE 30 ASIA PACIFIC: NGS SAMPLE PREPARATION MARKET SNAPSHOT
TABLE 193 ASIA PACIFIC: MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 194 ASIA PACIFIC: MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 195 ASIA PACIFIC: MARKET, BY WORKFLOW, 2021-2028 (USD MILLION)
TABLE 196 ASIA PACIFIC: MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
TABLE 197 ASIA PACIFIC: MARKET, BY METHOD, 2021-2028 (USD MILLION)
TABLE 198 ASIA PACIFIC: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 199 ASIA PACIFIC: MARKET FOR DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 200 ASIA PACIFIC: MARKET, BY END USER, 2021-2028 (USD MILLION)
12.4.1 CHINA
12.4.1.1 Favorable government initiatives for advanced life science research to aid market
TABLE 201 CHINA: NGS SAMPLE PREPARATION MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 202 CHINA: MARKET, BY WORKFLOW, 2021-2028 (USD MILLION)
TABLE 203 CHINA: MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
TABLE 204 CHINA: MARKET, BY METHOD, 2021-2028 (USD MILLION)
TABLE 205 CHINA: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 206 CHINA: MARKET FOR DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 207 CHINA: MARKET, BY END USER, 2021-2028 (USD MILLION)
12.4.2 JAPAN
12.4.2.1 Increased research funding to create growth opportunities for NGS-based studies
TABLE 208 JAPAN: NGS SAMPLE PREPARATION MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 209 JAPAN: MARKET, BY WORKFLOW, 2021-2028 (USD MILLION)
TABLE 210 JAPAN: MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
TABLE 211 JAPAN: MARKET, BY METHOD, 2021-2028 (USD MILLION)
TABLE 212 JAPAN: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 213 JAPAN: MARKET FOR DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 214 JAPAN: MARKET, BY END USER, 2021-2028 (USD MILLION)
12.4.3 INDIA
12.4.3.1 Decreasing sequencing costs and growing prevalence of target diseases to support market
TABLE 215 INDIA: NGS SAMPLE PREPARATION MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 216 INDIA: MARKET, BY WORKFLOW, 2021-2028 (USD MILLION)
TABLE 217 INDIA: MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
TABLE 218 INDIA: MARKET, BY METHOD, 2021-2028 (USD MILLION)
TABLE 219 INDIA: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 220 INDIA: MARKET FOR DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 221 INDIA: MARKET, BY END USER, 2021-2028 (USD MILLION)
12.4.4 AUSTRALIA
12.4.4.1 Increasing use of NGS platforms by academic institutes to propel market
TABLE 222 AUSTRALIA: NGS SAMPLE PREPARATION MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 223 AUSTRALIA: MARKET, BY WORKFLOW, 2021-2028 (USD MILLION)
TABLE 224 AUSTRALIA: MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
TABLE 225 AUSTRALIA: MARKET, BY METHOD, 2021-2028 (USD MILLION)
TABLE 226 AUSTRALIA: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 227 AUSTRALIA: MARKET FOR DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 228 AUSTRALIA: MARKET, BY END USER, 2021-2028 (USD MILLION)
12.4.5 SOUTH KOREA
12.4.5.1 Increasing spending by government on NGS research to augment market
TABLE 229 SOUTH KOREA: NGS SAMPLE PREPARATION MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 230 SOUTH KOREA: MARKET, BY WORKFLOW, 2021-2028 (USD MILLION)
TABLE 231 SOUTH KOREA: MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
TABLE 232 SOUTH KOREA: MARKET, BY METHOD, 2021-2028 (USD MILLION)
TABLE 233 SOUTH KOREA: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 234 SOUTH KOREA: PREPARATION MARKET FOR DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 235 SOUTH KOREA: MARKET, BY END USER, 2021-2028 (USD MILLION)
12.4.6 REST OF ASIA PACIFIC
TABLE 236 REST OF ASIA PACIFIC: NGS SAMPLE PREPARATION MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 237 REST OF ASIA PACIFIC: MARKET, BY WORKFLOW, 2021-2028 (USD MILLION)
TABLE 238 REST OF ASIA PACIFIC: MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
TABLE 239 REST OF ASIA PACIFIC: MARKET, BY METHOD, 2021-2028 (USD MILLION)
TABLE 240 REST OF ASIA PACIFIC: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 241 REST OF ASIA PACIFIC: MARKET FOR DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 242 REST OF ASIA PACIFIC: MARKET, BY END USER, 2021-2028 (USD MILLION)
12.4.7 ASIA PACIFIC: IMPACT OF RECESSION
12.5 LATIN AMERICA
TABLE 243 LATIN AMERICA: NGS SAMPLE PREPARATION MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 244 LATIN AMERICA: MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 245 LATIN AMERICA: MARKET, BY WORKFLOW, 2021-2028 (USD MILLION)
TABLE 246 LATIN AMERICA: MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
TABLE 247 LATIN AMERICA: MARKET, BY METHOD, 2021-2028 (USD MILLION)
TABLE 248 LATIN AMERICA: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 249 LATIN AMERICA: MARKET FOR DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 250 LATIN AMERICA: MARKET, BY END USER, 2021-2028 (USD MILLION)
12.5.1 BRAZIL
12.5.1.1 Rising focus on clinical genomics to drive demand for NGS
TABLE 251 BRAZIL: NGS SAMPLE PREPARATION MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 252 BRAZIL: MARKET, BY WORKFLOW, 2021-2028 (USD MILLION)
TABLE 253 BRAZIL: MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
TABLE 254 BRAZIL: MARKET, BY METHOD, 2021-2028 (USD MILLION)
TABLE 255 BRAZIL: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 256 BRAZIL: MARKET FOR DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 257 BRAZIL: MARKET, BY END USER, 2021-2028 (USD MILLION)
12.5.2 MEXICO
12.5.2.1 Growing biotechnology infrastructure development to support market
TABLE 258 MEXICO: NGS SAMPLE PREPARATION MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 259 MEXICO: MARKET, BY WORKFLOW, 2021-2028 (USD MILLION)
TABLE 260 MEXICO: MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
TABLE 261 MEXICO: MARKET, BY METHOD, 2021-2028 (USD MILLION)
TABLE 262 MEXICO: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 263 MEXICO: MARKET FOR DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 264 MEXICO: MARKET, BY END USER, 2021-2028 (USD MILLION)
12.5.3 REST OF LATIN AMERICA
TABLE 265 REST OF LATIN AMERICA: NGS SAMPLE PREPARATION MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 266 REST OF LATIN AMERICA: MARKET, BY WORKFLOW, 2021-2028 (USD MILLION)
TABLE 267 REST OF LATIN AMERICA: MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
TABLE 268 REST OF LATIN AMERICA: MARKET, BY METHOD, 2021-2028 (USD MILLION)
TABLE 269 REST OF LATIN AMERICA: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 270 REST OF LATIN AMERICA: MARKET FOR DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 271 REST OF LATIN AMERICA: MARKET, BY END USER, 2021-2028 (USD MILLION)
12.5.4 LATIN AMERICA: IMPACT OF RECESSION
12.6 MIDDLE EAST & AFRICA
12.6.1 INTRODUCTION OF COST-EFFECTIVE AND PORTABLE NGS TECHNOLOGIES TO STIMULATE MARKET
TABLE 272 MIDDLE EAST & AFRICA: NGS SAMPLE PREPARATION MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 273 MIDDLE EAST & AFRICA: MARKET, BY WORKFLOW, 2021-2028 (USD MILLION)
TABLE 274 MIDDLE EAST & AFRICA: MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
TABLE 275 MIDDLE EAST & AFRICA: MARKET, BY METHOD, 2021-2028 (USD MILLION)
TABLE 276 MIDDLE EAST & AFRICA: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 277 MIDDLE EAST & AFRICA: MARKET FOR DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 278 MIDDLE EAST & AFRICA: MARKET, BY END USER, 2021-2028 (USD MILLION)

13 COMPETITIVE LANDSCAPE (Page No. - 221)
13.1 INTRODUCTION
13.2 KEY STRATEGIES ADOPTED BY MARKET PLAYERS
TABLE 279 NGS SAMPLE PREPARATION MARKET: STRATEGIES ADOPTED BY KEY PLAYERS
13.3 REVENUE SHARE ANALYSIS (TOP 5 PLAYERS)
FIGURE 31 REVENUE ANALYSIS FOR TOP 5 COMPANIES (2019−2021)
13.4 MARKET SHARE ANALYSIS (2022)
FIGURE 32 MARKET: MARKET SHARE ANALYSIS OF TOP 5 PLAYERS (2022)
13.5 COMPANY EVALUATION QUADRANT
FIGURE 33 MARKET: COMPANY EVALUATION MATRIX (2022)
13.5.1 STARS
13.5.2 EMERGING LEADERS
13.5.3 PERVASIVE PLAYERS
13.5.4 PARTICIPANTS
13.6 COMPANY EVALUATION QUADRANT FOR START-UPS/SMES
13.6.1 PROGRESSIVE COMPANIES
13.6.2 STARTING BLOCKS
13.6.3 RESPONSIVE COMPANIES
13.6.4 DYNAMIC COMPANIES
FIGURE 34 MARKET: START-UPS/SMES EVALUATION QUADRANT (2022)
13.7 COMPETITIVE BENCHMARKING
13.7.1 DETAILED LIST OF START-UPS/SMES
TABLE 280 MARKET: DETAILED LIST OF START-UPS/SMES
13.7.2 COMPETITIVE BENCHMARKING OF KEY PLAYERS [START-UPS/SMES)
TABLE 281 MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS [START-UPS/SMES]
13.8 COMPETITIVE SCENARIO AND TRENDS
13.8.1 KEY DEALS
TABLE 282 MARKET: KEY DEALS
13.8.2 KEY PRODUCT LAUNCHES
TABLE 283 MARKET: KEY PRODUCT LAUNCHES
13.8.3 KEY EXPANSIONS
TABLE 284 MARKET: KEY EXPANSIONS

14 COMPANY PROFILES (Page No. - 241)
14.1 KEY PLAYERS
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
14.1.1 ILLUMINA, INC.
TABLE 285 ILLUMINA, INC.: COMPANY OVERVIEW
FIGURE 35 ILLUMINA, INC.: COMPANY SNAPSHOT (2021)
14.1.2 THERMO FISHER SCIENTIFIC INC.
TABLE 286 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
14.1.3 F. HOFFMANN-LA ROCHE LTD.
TABLE 287 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
14.1.4 PERKINELMER INC.
TABLE 288 PERKINELMER INC.: COMPANY OVERVIEW
FIGURE 38 PERKINELMER INC.: COMPANY SNAPSHOT (2022)
14.1.5 AGILENT TECHNOLOGIES, INC.
TABLE 289 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
14.1.6 DANAHER
TABLE 290 DANAHER: COMPANY OVERVIEW
14.1.7 BECTON, DICKINSON AND COMPANY
TABLE 291 BECTON, DICKINSON, AND COMPANY: COMPANY OVERVIEW
FIGURE 41 BECTON, DICKINSON, AND COMPANY: COMPANY SNAPSHOT (2021)
14.1.8 QIAGEN
TABLE 292 QIAGEN: COMPANY OVERVIEW
FIGURE 42 QIAGEN: COMPANY SNAPSHOT (2021)
14.1.9 MERCK KGAA
TABLE 293 MERCK KGAA: COMPANY OVERVIEW
FIGURE 43 MERCK KGAA: COMPANY SNAPSHOT (2021)
14.1.10 BIO-RAD LABORATORIES, INC.
TABLE 294 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW
FIGURE 44 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2021)
14.1.11 PROMEGA CORPORATION
TABLE 295 PROMEGA CORPORATION: COMPANY OVERVIEW
14.1.12 EUROFINS SCIENTIFIC
TABLE 296 EUROFINS SCIENTIFIC: COMPANY OVERVIEW
FIGURE 45 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2021)
14.1.13 BGI
TABLE 297 BGI: COMPANY OVERVIEW
14.1.14 10X GENOMICS
TABLE 298 10X GENOMICS: COMPANY OVERVIEW
FIGURE 46 10X GENOMICS: COMPANY SNAPSHOT (2021)
14.1.15 SYSMEX CORPORATION
TABLE 299 SYSMEX CORPORATION: COMPANY OVERVIEW
FIGURE 47 SYSMEX CORPORATION: COMPANY SNAPSHOT (2022)
14.2 OTHER PLAYERS
14.2.1 PSOMAGEN
14.2.2 ZYMO RESEARCH CORPORATION
14.2.3 TAKARA BIO INC.
14.2.4 NOVOGENE CO., LTD.
14.2.5 NEW ENGLAND BIOLABS
14.2.6 TECAN TRADING AG
14.2.7 OXFORD NANOPORE TECHNOLOGIES PLC
14.2.8 PACBIO
14.2.9 MEDGENOME
14.2.10 SWIFT BIOSCIENCES INC.
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

15 DISCUSSION GUIDE (Page No. - 294)
15.1 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
15.2 CUSTOMIZATION OPTIONS
15.3 RELATED REPORTS
15.4 AUTHOR DETAILS